IMPROVED VECTORS FOR THERAPEUTIC PROTEIN PRODUCTION

随着我们阐明越来越多的分泌性天然多肽的功能，潜在的生物治疗蛋白的多样性正在不断增加。此外，单链抗体正显示出作为各种疾病状态的治疗剂的前景。这种前景看好的蛋白质疗法的大量涌现要求改进生产蛋白质的方法，使其达到必要的规模，以满足动物疗效试验和临床使用的需求。我们最近设计了一种基于改良的牛乳头状瘤病毒(BPV)复制子的上体载体，该复制子可以作为稳定的Episome在各种细胞类型中保持，包括那些目前用于大规模蛋白质生产的细胞。在这一应用中，我们建议对该载体进行改造，以用于生产治疗性血浆蛋白。建议的商业应用：不可用

The diversity of potential biotherapeutic proteins is continuously rising as we elucidate the function of an ever-increasing number of secreted natural peptides. In addition, single-chain antibodies are showing promise as therapeutic agents for a variety of disease states. This profusion of potentially promising protein therapies demands improvements in the methods used for producing proteins on the scale necessary to meet demands for efficacy trials in animals and for use in the clinic. We have recently devised an episomal vector based upon a modified bovine papilloma virus (BPV) replicon that can be maintained as a stable episome in a wide variety of cell types, including those currently used for large-scale protein production. In this application, we propose the adaptation of this vector for use in the manufacture of therapeutic plasma proteins. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE